Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-2812 in Advanced or Metastatic RCC, Urothelial Cancer, or CRPC
NCT06966024Phase 1Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCC-2812 in renal cell carcinoma (RCC), urothelial carcinoma (UC) and castration-resistant prostate cancer (CRPC), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Dose-limiting Toxicities at 28 days, Treatment-emergent Adverse Events and Serious Adverse Events up to 42 months and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
DCC-2812
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06966024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966024.